Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common life-threatening monogenetic diseases characterized by progressive enlargement of fluid-filled renal cysts. Our previous study has shown that Ganoderma triterpenes (GT) retards PKD renal cyst development. In the present study we identified the effective ingredient of GT in suppression of kidney cyst development. Using an in vitro MDCK cystogenesis model, we identified ganoderic acid A (GA-A) as the most promising candidate among the 12 ganoderic acid (GA) monomers. We further showed that GA-A (6.25−100 μM) significantly inhibited cyst growth in MDCK cyst model and embryonic kidney cyst model in vitro, and the inhibitory effect was reversible. In kidney-specific Pkd1 knockout (kPKD) mice displaying severe cystic kidney disease, administration of GA-A (50 mg· kg−1 ·d−1, sc) significantly attenuated renal cyst development. In both MDCK cells and kidney of kPKD mice, we revealed that GA-A dose-dependently downregulated the Ras/MAPK signaling pathway. The expression of proliferating cell nuclear antigen (PCNA) was also suppressed, suggesting a possible effect of GA-A on cell proliferation. These experimental data suggest that GA-A may be the main ingredient of GT as a potential therapeutic reagent for treating ADPKD.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919–35.
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88:17–27.
Consortium T. I. P. K. D. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell. 1995;81:289–98.
Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science. 1996;272:1339–42.
Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321–37.
Lee SH, Somlo S. Cyst growth, polycystins, and primary cilia in autosomal dominant polycystic kidney disease. Kidney Res Clin Pract. 2014;33:73–8.
Cornec-Le Gall E, Audrezet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of PKD1 mutation influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24:1006–13.
Reule S, Sexton DJ, Solid CA, Chen SC, Collins AJ, Foley RN. ESRD from autosomal dominant polycystic kidney disease in the United States, 2001–2010. Am J Kidney Dis. 2014;64:592–9.
Ong AC, Devuyst O, Knebelmann B, Walz G. Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet. 2015;385:1993–2002.
Edwards ME, Chebib FT, Irazabal MV, Ofstie TG, Bungum LA, Metzger AJ, et al. Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2018;13:1153–61.
Lanktree MB, Chapman AB. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017;13:750–68.
Su L, Liu L, Jia Y, Lei L, Liu J, Zhu S, et al. Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation. Kidney Int. 2017;92:1404–18.
Rios JL, Andujar I, Recio MC, Giner RM. Lanostanoids from fungi: a group of potential anticancer compounds. J Nat Prod. 2012;75:2016–44.
Wu GS, Guo JJ, Bao JL, Li XW, Chen XP, Lu JJ, et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum—a review. Expert Opin Investig Drugs. 2013;22:981–92.
Gill BS, Navgeet, Kumar S. Ganoderic acid targeting multiple receptors in cancer: in silico and in vitro study. Tumour Biol. 2016;37:14271–90.
Gill BS, Navgeet, Mehra R, Kumar V, Kumar S. Ganoderic acid, lanostanoid triterpene: a key player in apoptosis. Investig New Drugs. 2018;36:136–43.
Xu JW, Zhao W, Zhong JJ. Biotechnological production and application of ganoderic acids. Appl Microbiol Biotechnol. 2010;87:457–66.
Yang HL. Ganoderic acid produced from submerged culture of Ganoderma lucidum induces cell cycle arrest and cytotoxicity in human hepatoma cell line BEL7402. Biotechnol Lett. 2005;27:835–8.
Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363–4.
Wang W, Geng X, Lei L, Jia Y, Li Y, Zhou H, et al. Aquaporin-3 deficiency slows cyst enlargement in experimental mouse models of autosomal dominant polycystic kidney disease. FASEB J. 2019;33:6185–96.
Zhou H, Gao J, Zhou L, Li X, Li W, Li X, et al. Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models. Am J Physiol Ren Physiol. 2012;302:F1234–42.
Sun Y, Zhou H, Yang BX. Drug discovery for polycystic kidney disease. Acta Pharmacol Sin. 2011;32:805–16.
Wang W, Li F, Sun Y, Lei L, Zhou H, Lei T, et al. Aquaporin-1 retards renal cyst development in polycystic kidney disease by inhibition of Wnt signaling. FASEB J. 2015;29:1551–63.
Lei L, Wang W, Jia Y, Su L, Zhou H, Verkman AS, et al. Aquaporin-3 deletion in mice results in renal collecting duct abnormalities and worsens ischemia-reperfusion injury. Biochim Biophys Acta, Mol Basis Dis. 2017;1863:1231–41.
Liang C, Tian D, Liu Y, Li H, Zhu J, Li M, et al. Review of the molecular mechanisms of Ganoderma lucidum triterpenoids: Ganoderic acids A, C2, D, F, DM, X and Y. Eur J Med Chem. 2019;174:130–41.
Kubota T, Asaka Y, Miura I, Mori H. Structures of ganoderic acid A and B, two new lanostane type bitter triterpenes from Ganoderma lucidum (FR.) KARST. Helv Chim Acta. 1982;65:611–9.
Kikuchi T, Kanomi S, Kadota S, Murai Y, Tsubono K, Ogita ZI. Constituents of the fungus Ganoderma lucidum (Fr.) Karst. I Structures of ganoderic acids C2, E, I, and K, lucidenic acid F and related compounds. Chem Pharm Bull. 1986;34:3695–712.
Kikuchi T, Matsuda S, Kadota S, Murai Y, Ogita Z. Ganoderic acid D, E, F, and H and lucidenic acid D, E, and F, new triterpenoids from Ganoderma lucidum. Chem Pharm Bull. 1985;33:2624–7.
Yue QX, Cao ZW, Guan SH, Liu XH, Tao L, Wu WY, et al. Proteomics characterization of the cytotoxicity mechanism of ganoderic acid D and computer-automated estimation of the possible drug target network. Mol Cell Proteom. 2008;7:949–61.
Che XQ, Li SP, Zhao J. Ganoderma triterpenoids from aqueous extract of Ganoderma lucidum. Zhongguo Zhong Yao Za Zhi. 2017;42:1908–15.
Li BM, Gu HF, Li Y, Liu C, Wang HQ, Kang J, et al. Determination of nine triterpenoid acids from Ganoderma lucidum of different producting areas by HPLC. Zhongguo Zhong Yao Za Zhi. 2012;37:3599–603.
Liu DL, Li YJ, Yang DH, Wang CR, Xu J, Yao N, et al. Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. Int J Oncol. 2015;46:2029–38.
Miyamoto I, Liu J, Shimizu K, Sato M, Kukita A, Kukita T, et al. Regulation of osteoclastogenesis by ganoderic acid DM isolated from Ganoderma lucidum. Eur J Pharmacol. 2009;602:1–7.
Tang W, Liu JW, Zhao WM, Wei DZ, Zhong JJ. Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. Life Sci. 2006;80:205–11.
Gill BS, Kumar S, Navgeet. Evaluating anti-oxidant potential of ganoderic acid A in STAT 3 pathway in prostate cancer. Mol Biol Rep. 2016;43:1411–22.
Yao X, Li G, Xu H, Lu C. Inhibition of the JAK-STAT3 signaling pathway by ganoderic acid A enhances chemosensitivity of HepG2 cells to cisplatin. Planta Med. 2012;78:1740–8.
Jiang J, Grieb B, Thyagarajan A, Sliva D. Ganoderic acids suppress growth and invasive behavior of breast cancer cells by modulating AP-1 and NF-kappaB signaling. Int J Mol Med. 2008;21:577–84.
Rushworth LK, Hindley AD, O’Neill E, Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol. 2006;26:2262–72.
Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol. 2011;301:C522–9.
Cao FR, Feng L, Ye LH, Wang LS, Xiao BX, Tao X, et al. Ganoderic acid A metabolites and their metabolic kinetics. Front Pharmacol. 2017;8:101.
Cao FR, Xiao BX, Wang LS, Tao X, Yan MZ, Pan RL, et al. Plasma and brain pharmacokinetics of ganoderic acid A in rats determined by a developed UFLC-MS/MS method. J Chromatogr B Anal Technol Biomed Life Sci. 2017;1052:19–26.
Lu J, Qin JZ, Chen P, Chen X, Zhang YZ, Zhao SJ. Quality difference study of six varieties of Ganoderma lucidum with different origins. Front Pharmacol. 2012;3:57. https://doi.org/10.3389/fphar.2012.00057.
Nakagawa T, Zhu Q, Tamrakar S, Amen Y, Mori Y, Suhara H, et al. Changes in content of triterpenoids and polysaccharides in Ganoderma lingzhi at different growth stages. J Nat Med. 2018;72:734–44.
This work was supported by the National Natural Science Foundation of China grants 81620108029, 81330074, 81261160507, 81170632, and 81873597 and the Beijing Natural Science Foundation grant 7172113. We thank Peter Igarashi and Stefan Somlo for the Ksp-Cre and Pkd1flox/flox mice.
The authors declare no competing interests.
About this article
Cite this article
Meng, J., Sai-zhen Wang, He, J. et al. Ganoderic acid A is the effective ingredient of Ganoderma triterpenes in retarding renal cyst development in polycystic kidney disease. Acta Pharmacol Sin 41, 782–790 (2020). https://doi.org/10.1038/s41401-019-0329-2
- Ganoderma triterpenes
- Ganoderic acids
- Ganoderic acid A
- kPKD mice
- Ras/MAPK signaling pathway